Use of FMT in PD animal models was associated with increased dopamine production in the striatum, reversal of microglial and astrocyte activation, as well as decreased gut and brain TLR4 expression [92]; additionally, studies involving a small number of individuals with PD have shown FMT potential in decreasing non-motor symptoms [93, 94]. The gene discussed is TLR4; the disease is Parkinson disease.